Adjuvant effects of novel water/oil emulsion formulations on immune responses against infectious bronchitis (IB) vaccine in mice.

Vaccines have long made use of adjuvants to boost the immune response of the body and reduce the amount of vaccine needed as well as the expense of producing the vaccine. Many vaccine adjuvants are in development, but their application in veterinary vaccinations is restricted due to their lack of efficacy or undesirable side effects. For this reason, it is essential to develop novel adjuvants. To address the issue that the currently available infectious bronchitis (IB) vaccine often fails to produce sufficient immune responses, Coral Biotechnology tested two of their newly developed water-in-oil (W/O) type emulsion adjuvants (Coralvac RZ 528 and Coralvac RZ 506) in the IB vaccine. These adjuvants were tested in a mouse model to determine whether it worked with an inactive IBV H120 vaccine. Vaccine formulations were prepared by combining a virus concentration of 1 × 106 EID50/0.1 ml with an emulsion of the W/O type in a specific ratio. Once the formulations were ready, it was injected intramuscularly as a single dosage, and the mice were monitored for 21 days afterwards. The results showed that anti-IB antibody titer (IgG and IgG1), CD3+ CD8+ T cell responses as well as IFN- γ cytokine production, and splenocyte proliferation were all considerably higher in the IBV H120 with Coralvac RZ 528 and IBV H120 with Coralvac RZ 506 formulation groups than in the viral control group. According to our findings, the humoral and cellular immune responses of mice were significantly enhanced by these novel vaccine adjuvants. Thus, our results provide evidence that the W/O type emulsion adjuvants developed by Coral Biotechnology may be a useful adjuvant in IBV vaccines.

Eficacia del tratamiento antibiótico en la bronquitis aguda / Efficacy of antibiotic treatment in acute bronchitis

Partiendo de una viñeta clínica la autora plantea el siguiente interrogante: ¿En pacientes mayores de 65 años con diag-nóstico probable de bronquitis aguda, el uso de antibióticos produce mejora en algún parámetro clínico?Luego de realizar una busqueda bibliográfica se resumen la evidencia publicada en una reciente revisión sistemática, la cual concluye que si bien existen beneficios estadísticamente significativos en algunos resultados de interés, estos no parecen tener impacto clínico teniendo en cuenta la naturaleza habitualmente autolimitada y benigna de esta enfermedad y la posibilidad de efectos colateales relacionados con el tratamiento. Es importante destacar sin embargo que la eviden-cia resultó limitada para abordar cabalmente a la población anciana afectada por este problema. (AU)

Moved by a clinical vignette, the author propose the following question: In patients over 65 with probable diagnosis of acute bronchitis, does the use of antibiotics produce improvement in any clinical outcome?After carrying out a bibliographic search, the evidence published in a recent systematic review is summarized, which concludes that although there are statistically significant benefits in some results of interest, these do not seem to have clinical impact, tak-ing into account the usually self-limited and benign nature of this disease and the possibility of collateral effects related to the treatment. It is important to highlight, however, that the evidence was limited to fully address the elderly population affected by this problem. (AU)